KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCA Healthcare (HCA) Depreciation & Amortization (CF) (2016 - 2025)

HCA Healthcare (HCA) has disclosed Depreciation & Amortization (CF) for 14 consecutive years, with $911.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 6.43% to $911.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 billion, a 6.37% increase, with the full-year FY2025 number at $3.5 billion, up 6.37% from a year prior.
  • Depreciation & Amortization (CF) was $911.0 million for Q4 2025 at HCA Healthcare, up from $889.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $911.0 million in Q4 2025 to a low of $697.0 million in Q1 2021.
  • A 5-year average of $786.7 million and a median of $766.0 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): grew 9.97% in 2021, then grew 2.67% in 2023.
  • HCA Healthcare's Depreciation & Amortization (CF) stood at $728.0 million in 2021, then grew by 3.02% to $750.0 million in 2022, then rose by 5.2% to $789.0 million in 2023, then grew by 8.49% to $856.0 million in 2024, then rose by 6.43% to $911.0 million in 2025.
  • Per Business Quant, the three most recent readings for HCA's Depreciation & Amortization (CF) are $911.0 million (Q4 2025), $889.0 million (Q3 2025), and $863.0 million (Q2 2025).